Focus: Bonesupport is a Frankfurt-based biotechnology company specializing in bone repair technology, with a focused portfolio in musculoskeletal indications. The company operates as a publicly traded entity (OM:BONEX) with recent momentum in profitability and analyst interest.
Profile data last refreshed 14h ago · AI intelligence enriched 2w ago
Best for commercial, finance, and operations professionals seeking stability in a profitable niche biotech; less ideal for researchers seeking frontier-stage drug discovery roles.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Bonesupport
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Bonesupport's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Is Strong Quarterly Earnings Altering The Investment Case For Bonesupport Holding (OM:BONEX)? - Simply Wall Street
Is Strong Quarterly Earnings Altering The Investment Case For Bonesupport Holding (OM:BONEX)? Simply Wall Street
Bonesupport Holding (OM:BONEX) Q3 Earnings Sharpen Focus On Rich Valuation - Simply Wall Street
Bonesupport Holding (OM:BONEX) Q3 Earnings Sharpen Focus On Rich Valuation Simply Wall Street
Spotlighting Basic-Fit And 2 Other European Growth Companies With Insider Ownership - Simply Wall St
Spotlighting Basic-Fit And 2 Other European Growth Companies With Insider Ownership Simply Wall St
European Undervalued Small Caps With Insider Activity To Explore In October 2026 - Simply Wall Street
European Undervalued Small Caps With Insider Activity To Explore In October 2026 Simply Wall Street
Why NEJM Study Publication Matters For Bonesupport Holding (OM:BONEX) Shares - Simply Wall Street
Why NEJM Study Publication Matters For Bonesupport Holding (OM:BONEX) Shares Simply Wall Street
It’s crunch time for BoneSupport, one of Europe’s most shorted stocks - Financial Times
It’s crunch time for BoneSupport, one of Europe’s most shorted stocks Financial Times
Showing 6 of 10 news items
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company